Higher Amyloid and Tau Burden Is Associated With Faster Decline on a Digital Cognitive Test
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective A 2‐min digital clock‐drawing test (DCTclock) captures more granular features of the clock‐drawing process than the pencil‐and‐paper clock‐drawing test, revealing more subtle deficits at the preclinical stage of Alzheimer's disease (AD). A previous cross‐sectional study demonstrated that worse DCTclock performance was associated with
Jessie Fanglu Fu +16 more
wiley +1 more source
Cost-effectiveness analysis of endovascular treatment with or without intravenous thrombolysis in acute ischemic stroke [PDF]
, 2022 Adnan I. Qureshi +6 more
openalex +1 more source
Portable Low‐Field Magnetic Resonance Imaging in People With Human Immunodeficiency Virus
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective The aging population of people with HIV (PWH) raises heightened concerns regarding accelerated aging and dementia. Portable, low‐field MRI (LF‐MRI) is an innovative technology that could enhance access and facilitate routine monitoring of PWH.
Annabel Sorby‐Adams +14 more
wiley +1 more source
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective This study aims to identify both fluid and neuroimaging biomarkers for CSF1R‐RD that can inform the optimal timing of treatment administration to maximize therapeutic benefit, while also providing sensitive quantitative measurements to monitor disease progression.
Tomasz Chmiela +13 more
wiley +1 more source
The Costs and Cost-Effectiveness of a District-Strengthening Strategy to Mitigate the 3 Delays to Quality Maternal Health Care: Results From Uganda and Zambia [PDF]
, 2019 Benjamin Johns +12 more
openalex +1 more source
Correction to: Cost‑Effectiveness of Empirical Bismuth‑Based Quadruple Therapy and Tailored Therapy After Clarithromycin Resistance Tests for Helicobacter pylori Eradication [PDF]
, 2021 Young Woon Chang +6 more
openalex +1 more source
Inhibition of Classical and Alternative Complement Pathway by Ravulizumab and Eculizumab
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective To explore the feasibility of classical (CH50) and alternative (AH50) complement pathway activity as potential biomarkers for treatment guidance and monitoring during therapy with ravulizumab in patients with generalized myasthenia gravis (gMG) and compare these to therapeutic drug monitoring under eculizumab.
Lea Gerischer +14 more
wiley +1 more source
Estimating a cost‐effectiveness threshold for the Spanish NHS
Health Economics, 2018 L. Vallejo-Torres +2 more
semanticscholar +1 more source